Excessive Weight Gain Associated With Dolutegravir Initiation in a 10-Year-Old Female With Perinatally Acquired Human Immunodeficiency Virus: A Case Report and Review of the Literature
- 25 May 2020
- journal article
- review article
- Published by Oxford University Press (OUP) in Journal of the Pediatric Infectious Diseases Society
- Vol. 10 (3), 373-375
- https://doi.org/10.1093/jpids/piaa052
Abstract
Children with perinatally acquired human immunodeficiency virus (PHIV) face a lifetime of combination antiretroviral treatment that often includes dolutegravir (DTG). DTG, an integrase strand inhibitor that has been linked to weight gain in adults, is increasingly being used in children. Understanding its potential short- and long-term sequelae in children is critically important. We report a case of excessive weight gain in a child with PHIV on DTG and provide a brief literature review.Keywords
This publication has 6 references indexed in Scilit:
- HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cellsPLOS ONE, 2020
- Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical TrialsClinical Infectious Diseases, 2019
- Greater Weight Gain in Treatment-naive Persons Starting Dolutegravir-based Antiretroviral TherapyClinical Infectious Diseases, 2019
- Long-Term Safety and Efficacy of Dolutegravir in Treatment-Experienced Adolescents With Human Immunodeficiency Virus Infection: Results of the IMPAACT P1093 StudyJournal of the Pediatric Infectious Diseases Society, 2019
- Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor–Based RegimensJAIDS Journal of Acquired Immune Deficiency Syndromes, 2017
- Association between postnatal catch-up growth and obesity in childhood: prospective cohort studyBMJ, 2000